Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD116/CSF2RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD116/CSF2RA ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD116/CSF2RA Products |
| Gene Delivery | CD116/CSF2RA Lentivirus Particles Full-length ORF for stable cell lines. High Titer (>10^8 TU/ml). Puromycin selection. |
View CD116/CSF2RA Products |
| Benchmark Ab | Anti-CD116/CSF2RA (Mavrilimumab Biosimilar Sequence) Recombinant positive control for binding/inhibition assays. |
View CD116/CSF2RA Products |
| Validator | CD116/CSF2RA siRNA Set For knockdown verification and specificity controls. |
View CD116/CSF2RA Products |
| Related Target A | CSF2RB (CD131) Obligate signaling partner; required for high-affinity GM-CSF binding and heterodimeric assay design. |
View CSF2RB Products |
| Related Target B | GM-CSF (CSF2) Natural ligand for competitive binding assays and pathway activation control. |
View CSF2 Products |
| Related Target C | IL3RA (CD123) Shared common beta-chain (CSF2RB); essential for selectivity counter-screening in AML combination pipelines. |
View IL3RA Products |
| Related Target D | CSF1R (CD115) M-CSF Receptor; myeloid differentiation control; selectivity screening for macrophage-related indications. |
View CSF1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Competition & Epitope Mapping | HEK293 Expressed ECD-Fc with native conformational epitopes. Theoretical MW verified by Mass Spec. |
| Cross-species Cyno/Mouse Evaluation | Human / Cynomolgus / Mouse ortholog proteins available; all >95% purity, sequence verified by mass spec. |
| Functional Receptor Complex Assembly | CSF2RA and CSF2RB ECD-Fc panel supports binary/ternary complex SPR/BLI assembly assays; HEK293 expression ensures proper folding. |
| Internalization for ADC Development | Full-length Lentivirus particles for generation of CD116-positive reporter cell lines preserving native internalization kinetics. |
| Pathway Specificity (vs IL-3/IL-5) | Strictly verified homolog panel (IL3RA, IL5RA) and CSF2RB co-receptor for off-target counter-screening. |
| Lack of Clinical Controls | Anti-CSF2RA Benchmark Antibody (Mavrilimumab sequence) included as recombinant reference. |
| False Positives | Validated siRNA set for target-specificity confirmation in cell-based assays; clinical benchmark antibodies as positive controls. |
Live CD116/CSF2RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CD116/CSF2RA is entering a critical phase as first-in-class receptor-targeting biologics advance through late-stage clinical trials. Distinct from ligand-targeting strategies (anti-GM-CSF), direct CD116 antagonism offers potential for cell-type specific modulation of the GM-CSF pathway. Kiniksa Pharmaceuticals' mavrilimumab (formerly MedImmune/AstraZeneca) leads the clinical race, demonstrating differentiated efficacy in rheumatoid arthritis and giant cell arteritis compared to conventional cytokine blockade.
Simultaneously, emerging preclinical evidence positions CD116 as a viable ADC target for acute myeloid leukemia (AML), where receptor overexpression on leukemic blasts enables targeted payload delivery. As the field pivots from broad immunosuppression to precision myeloid cell modulation, demand for high-fidelity reagents supporting internalization kinetics and cross-species validation has intensified. The next wave of R&D is targeting precise receptor blockade without compromising basal myeloid function, pushing the need for highly specific binding kinetics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Kiniksa Pharmaceuticals (Mavrilimumab) | Rheumatoid Arthritis, Giant Cell Arteritis | Ligand Competition & Cyno Cross-reactivity (Need high-purity ECD-Fc) |
| ADC | Emerging Preclinical Programs | AML, Solid Tumors | Internalization Assay (Need full-length Lentivirus stable lines) |
| Bispecific | Research Phase (Academic/BI) | Autoimmune Diseases | Heterodimer Validation & Dual-target Binding (Need Cross-reactive Abs) |
| CAR-T/NK | Preclinical | Inflammatory Conditions | Cell Surface Density Calibration (Need quantitative Lentivirus standards) |
Development Considerations & Assay Strategy
Differentiation Factors: Affinity/blocking efficiency balance for antagonist mAbs; internalization kinetics critical for ADC; rigorous cross-species validation (cyno/mouse); subfamily off-target specificity vs IL-3R/IL-5R. TarMart provides high-purity ECD-Fc (HEK293, >95%), lentivirus for stable cell lines, and a homolog panel for counter-screening.